BTK and B-cell chronic lymphocytic leukemia: Frontline therapies for CLL include chemoimmunotherapy regimens, monoclonal CD20 antibodies, inhibitors of the Bruton’s tyrosine kinase (BTK), and inhibitor of the B-cell lymphoma 2 (BCL2) protein (Eichhorst et al., 2021).